GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Central Pharmaceuticals Ltd (DHA:CENTRALPHL) » Definitions » Debt-to-Asset

Central Pharmaceuticals (DHA:CENTRALPHL) Debt-to-Asset : 0.21 (As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Central Pharmaceuticals Debt-to-Asset?

Central Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was BDT36.50 Mil. Central Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was BDT231.98 Mil. Central Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2022 was BDT1,302.27 Mil. Central Pharmaceuticals's debt to asset for the quarter that ended in Sep. 2022 was 0.21.


Central Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Central Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Central Pharmaceuticals Debt-to-Asset Chart

Central Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.17 0.18 0.21 0.21

Central Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Jun23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.20 0.21 0.21 0.21

Competitive Comparison of Central Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Central Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Central Pharmaceuticals's Debt-to-Asset falls into.



Central Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Central Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(36.497 + 231.978) / 1267.831
=0.21

Central Pharmaceuticals's Debt-to-Asset for the quarter that ended in Sep. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(36.497 + 231.978) / 1302.267
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Central Pharmaceuticals  (DHA:CENTRALPHL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Central Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Central Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Central Pharmaceuticals (DHA:CENTRALPHL) Business Description

Traded in Other Exchanges
N/A
Address
South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished formulation products for general people, hospitals, clinics, government organizations, corporations, and other non-government organizations. Its product portfolio encompasses therapeutic categories including gastrointestinal, anti-infective, vitamins and minerals, allergy cough and cold, analgesic and musculoskeletal, dermatological, oral rehydration salt, and others. The products are in the dosage forms of tablets, capsules, liquid, and ointments.

Central Pharmaceuticals (DHA:CENTRALPHL) Headlines

No Headlines